Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID-19: A phase 2a, open-label, single-dose escalation study.
Prins MLM, van der Plas JL, Vissers MFJM, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V, Zimmermann M, Drake RF, Burggraaf J, Groeneveld GH, Kamerling IMC.
Prins MLM, et al. Among authors: drake rf.
Br J Clin Pharmacol. 2023 Mar;89(3):1105-1114. doi: 10.1111/bcp.15560. Epub 2022 Oct 24.
Br J Clin Pharmacol. 2023.
PMID: 36214216
Free PMC article.
Clinical Trial.